Exicure, Inc. Common Stock
XCURExicure, Inc. (XCUR) is a biotechnology company focused on developing innovative nucleic acid therapeutics using its proprietary spherical nucleic acid (SNA) technology. The company aims to address challenging genetic and inflammatory diseases with its platform, which facilitates targeted gene regulation and modulation. Based in Chicago, Exicure leverages its scientific expertise to advance therapies in areas such as oncology, dermatology, and immunology.
Company News
Exicure, Inc. announced it will present positive Phase 2 trial data for burixafor at the 2026 Tandem Meetings in Salt Lake City. The trial evaluated burixafor's ability to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous transplantation, with 89.7% of patients meeting the primary endpoint and demonstratin...
Exicure reported a net loss of $2.4 million in Q3 2025, with reduced cash reserves and insufficient funding to continue operations. The company is exploring strategic alternatives and seeking additional financing.
Biotechnology company Exicure reported no revenue in Q2 2025, a widened net loss of $2.6 million, and a critical need for additional financing after acquiring GPCR Therapeutics USA Inc. The company is pivoting to focus on stem cell mobilization therapies for blood disorders.
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. FMC posted adjusted earnings of $1.07 per share, missing market estimates of $1.08 per share. The company’s quarterly sales came in at $1.15 billion versus expectations of $1.25 billion. FMC shar...
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance. Palantir said fourth-quarter revenue increased 20% year-over-year to $608 million, which beat the consensus estimate of $602.41 million, according to B...
